Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicenna Therapeutics Corp. has reported promising results from its ongoing ABILITY-1 study, showing significant efficacy of its MDNA11 treatment in combination with KEYTRUDA for challenging cancer types. The study highlights potential breakthroughs in treating cancers typically resistant to immunotherapy, with a 70-year-old patient achieving a complete response and demonstrating the potential of MDNA11 to enhance existing treatments.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.